Abstract
Background
Bladder cancer (BC) belongs to the most frequent cancer types. The diagnostic process is still long and costly, with a high percentage of false-positive or -negative results. Due to the cost and lack of effectiveness, older methods need to be supplemented or replaced by a newer more reliable method. In this regard, proteins and glycoproteins pose high potential.
Methods
We performed an online search in PubMed/Medline, Scopus, and Web of Science databases to find relevant studies published in English up until May 2023. If applicable, we set the AUC threshold to 0.90 and sensitivity/specificity (SN/SP) to 90%.
Findings
Protein and glycoprotein biomarkers are a demonstrably viable option in BC diagnostics. Cholinesterase shows promise in progression-free survival. BLCA-4, ORM-1 along with HTRA1 in the detection of BC. Matrix metallopeptidase 9 exhibits potential for stratification of muscle-invasive subtypes with high negative predictive value for aggressive phenotypes. Distinguishing non-muscle invasive subtypes benefits from Keratin 17. Neu5Gc-modified UMOD glycoproteins pose potential in BC diagnosis, while fibronectin, laminin-5, collagen type IV, and lamprey immunity protein in early detection of BC.
Similar content being viewed by others
Introduction
Bladder cancer (BC) belongs to the top ten most common cancers worldwide, with over 200,000 yearly new cases in the European Union (EU) (EAU Guidelines 2023; Sung et al. 2021). Globally, BC is more frequent in males and also depends on the population and region. The American Cancer Society (ACS) reported that 90% of BC cases are in patients over 55 years of age, with an average age of 73.
At the time of diagnosis, the tumor can be characterized as non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC), while about 90% of these tumors are of urothelial origin (Kaseb and Aeddula 2023). Diagnosis, therapy, and prognosis of NMIBC suffer from an unpredictable recurrence rate and a chance of progression, while MIBC often represents aggressive neoplasms with peripheral invasion, metastases, and poor response to treatment (Cho et al. 2009; Fukumoto et al. 2016). Classic immunohistochemical analysis of cancer tissue is widely utilized, but studies show that this method is unsuitable for the use of prediction of recurrence and progression (Bevizova et al. 2013; Repiska et al. 2010). Over the last few years, the European Association of Urology (EAU) has slowly adopted and implemented molecular markers into BC diagnosis, but they are not yet suitable for routine application, and cystoscopy in combination with cytology is still the gold standard (EAU Guidelines 2020, 2021, 2022).
This year, a new test for the prediction of future BC has been presented. The UroAmp test was effective in predicting 66% of future BCs in urine samples collected 12 years ago, at least 6 years before clinical diagnosis. The test was truly negative in 94 of the 98 participants (96%) who would not develop BC in the future. Mutations were found in 71% of urine samples in patients with already visible tumors. Mutations were not found in 94% of patients with a negative cystoscopy (EAU Guidelines 2023; Medscape 2023). Although not yet officially approved by the EAU or the American Urological Association (AUA), the specificity (SP) of 94% is a significant boost over the lower SN of already approved tests (e.g., BTA stat/TRAK, NMP22, Cell Search, UroVysion, uCyt +) at least except for the recently approved Uromonitor with specificity/sensitivity (SP/SN) of 73.5/93.2% (Lee et al. 2023).
In this review, we focused on published proteomic, and glycomic molecular markers associated with BC. The selection of proteomic biomarkers was based on the reported high sensitivity and specificity threshold. Finding new viable and more accurate biomarkers that could be used in screening will significantly enhance the diagnostic process. It will also supplement conventional diagnostic methods such as urine cytology and cystoscopy, with a future possibility to even replace them.
Materials and methods
We performed an online search in PubMed/Medline, Scopus, and Web of Science using the terms “bladder cancer”, in combination with “glycomic”, “glycoprotein”, “proteomic”, “protein” and “markers” or “biomarkers” published up until May 2023. If applicable, we set the threshold of sensitivity and specificity (SN/SP) to be at least 90% for primary markers; while for panel markers, at least one variable needed to be over 90%. Panel markers are specified as possible synergic diagnostic biomarkers, that could enhance each other’s potential in a diagnostic panel.
Taking ground in the recent knowledge, we do not prefer the notion of an independent prognostic marker, since every marker and test has shown flawed results depending on sample preparation, transportation, or examination. Test results are also affected by inter- and intra-individual variabilities, such as the presence of a urologic condition or genetic variation.
The threshold of SN/SP is mainly used in proteomic markers with the addition of the area under the curve (AUC) score, positive predictive value (PPV), and negative predictive value (NPV), which were equally set to 0.90 and more, to ensure high diagnostic potential. As genes and various RNA molecules are usually not evaluated by SN/SP or AUC, the threshold of inclusion has been set on a repeated statistical significance reported by researchers.
Proteomic biomarkers
As conventional methods face limitations, the comprehensive analysis of proteomics emerges as a beacon of hope for overcoming diagnostic challenges. Discussed proteomic biomarkers are presented in Table 1.
Cholinesterase (ChE) is a predictor of progression-free survival (PFS). ChE is a soluble enzyme in human plasma and serum. Human blood contains ten times more butyrylcholinesterase (BuChE) than acetylcholinesterase (AChE). The average human serum contains 4–5 mg BuChE per liter, but only 0.5 mg AChE per liter of blood. A retrospective study on 1117 NMIBC patients by Kimura et al., reported a 5-year PFS in patients with low and normal ChE levels were 93.2% and 91.4%, respectively (p = 0.053). ChE was significantly associated with shorter recurrence-free survival (RFS). ChE was also a strong predictor of disease recurrence (Kimura et al. 2018).
Li et al. analyzed the circulating FGF19, 21, and 23 levels in 67 patients. All median serum levels of BC patients deviated from healthy controls. All were significant predictors of BC, and ROC (receiver operating characteristic) curves with AUC—0.674 (p = 0.015); AUC—0.918 (p < 0.001); AUC—0.897 (p < 0.001), respectively. FGF21 and FGF23 show promise, although mainly missing the SN/SP threshold, save for the specificity of 96.43% for FGF23. FGF21 (p = 0.025) was increased in patients with a history of recurrence (Li et al. 2019).
In a meta-analysis by Huang et al., cytokeratin 19 fragment (CYFRA 21-1) pooled SN from urine and serum were 82% and 42%, respectively. The pooled SP was 80% and 94%, respectively (Huang et al. 2015). A recent meta-analysis by Zhu et al. did not differentiate the source of the marker between serum and urine. The reported pooled SN/SP of 69/81% with AUC—0.89 is a confirmation of the previous meta-analysis. Based on current knowledge we can conclude that CYFRA 21-1 is not suitable as an independent prognostic or diagnostic marker, although the SN/SP in urine could contribute to a combined urine protein panel.
Calcium ion-binding proteins S100A8 (MRP8) and S100A9 (MRP14), along with S100A4, CA1 (carbonic anhydrase 1), and Annexin V (annexin 5) proteins were studied by Bansal et al., with reported significant differences in pre-and post-operative levels in BC patients (Bansal et al. 2016). Namely, S100A9 (AUC—0.957; SN 92.3%; SP 83.6%) and Annexin V (AUC—0.921; SN 90.4%; SP 80.0%) showed the greatest promise, however, Yasar et al. reported no difference between serum levels of S100A8 and S100A9 in the study or control group (Yasar et al. 2017). These markers show promise in research of prostate cancer (Novakova et al. 2014; Grebhardt et al. 2014). In the later study, Calprotectin serum levels were significantly elevated in the whole study group if compared to controls, although without the possibility of stratifying patients based on stage or grade. Urine calprotectin levels were significantly higher in the study group, with an additional two- to threefold elevation in MIBC (T2–4) compared to NMIBC (Ta and T1).
Urine BTA (bladder tumor antigen) was higher in the study group, but due to the long intervals of chosen stage/grade groups unviable for patient stratification (Yasar et al. 2017).
A recent study by Amano et al., on the heterogeneous nuclear ribonucleoprotein A3 (HNRNPA3) expression, was shown to be significantly associated with lymph node metastasis and S100A8, S100A9, and uroplakin III expressions (Amano et al. 2021).
A pre- and post-operative evaluation of targeted serum metabolic biomarkers by Gupta et al., reported AUC of 0.868–0.934, with SN/SP of around 80% for dimethyl amine (DMA), glutamine, lactate, histidine, and valine. While all missed the 90% threshold, these serum biomarkers could be used in a combined serum pallet (Gupta et al. 2020).
The matrix metallopeptidase 9 (MMP-9) was studied by Candido et al., where the higher urinary levels of NGAL, MMP-9, and NGAL/MMP-9 complex were recorded in the group of current smokers, but no dietary impact was observed. Significant elevations occurred in MIBC (T2–T4) and non-papillary BCs. ROC analysis proposed MMP-9 as a viable marker (AUC—0.68), but for MIBC, the performance was significantly better (AUC—0.90) with NPV of 97% for aggressive phenotypes of BC (Candido et al. 2016). The participation of the MMP9 axis was lately studied in association with miRNA and circRNA, where inhibition of MMP9 protein degradation by miRNA-516a promoted cancer metastasis, and MMP9 upregulation in circ0001361-overexpressed BC cells promoted cell migration and invasion (Chang et al. 2020; Liu et al. 2020).
The study of Orywall et al. on serum ADH (alcohol dehydrogenase) isoenzymes and ALDH (aldehyde dehydrogenase) activity found a significantly higher total activity of ADH in sera of both, low-grade and high-grade BC patients, with ADH activity (AUC—0.848; SN 81.5%; SP 98.1%; PPV 97.4%; NPV 92.3%) (Orywal et al. 2017, 2018).
Survivin SN/SP performance in research is reported in intervals of 60–80%, however novel approach by Jazayeri et al., using the survivin antibody-conjugated gold nanoparticles (GNPs) dependent on visible color changes and colorimetric detection (reader devices not needed), allowing for the protein to be detected in the urine of patients with both LG and HG tumors. By this method, LG tumors could be diagnosed by visible color changes and colorimetric detection (Jazayeri et al. 2020).
Hyaluronic acid (HA) is synthesized at the plasma membrane by any one of the three hyaluronan synthases (HAS). HAS1, HAS2, and HAS3 are transmembrane proteins, which synthesize different sizes of HA at different kinetic rates (Adamia et al. 2005). HAS1 and HAS2 expression increases following malignant transformation and promotes tumor growth (Itano et al. 2004). The expression of HAS1 was studied in BC in relation to the urinary HA test (Golshani et al. 2007). The study demonstrated that HAS1 type HA-synthase is expressed in BC cells and the expression is upregulated, both at the transcriptional and translational levels, suggesting that HAS1 expression may have prognostic potential related to tumor recurrence and progression. Similar works showed that HAS1 modulates HA and CD44 levels, affecting tumor growth and progression in BC, and HAS1 mRNA expression was associated with BC metastasis (Golshani et al. 2008; Kramer et al. 2011).
Hyaluronidase-1 (HYAL-1) is the major hyaluronidase expressed in BCa cells and is an accurate marker for high-grade BC (Eissa et al. 2005). High expression of Hyal1 has been suggested to predict MIBC and recurrent BC and is associated with metastasis and decreased disease-specific survival (Kramer et al. 2010). However, in pT1 BC, the expression of HYAL-1 did not have any prognostic importance (Mammadov et al. 2014). In the recent meta-analysis, HYAL-1 demonstrated the highest PPV. In terms of accuracy indicators, HYAL-1, UCA1, and survivin had the highest accuracy concluding that HYAL-1 and survivin are suitable urine biomarkers for BC diagnosis. This ranks HYAL-1 as the most promising urine biomarker (Dong et al. 2021).
BLCA-4 is a member of the nuclear matrix protein family and is involved in tumor cell proliferation, survival, and angiogenesis (Lotan and Roehrborn 2003). BLCA-4 was reported to be the most sensitive and specific urinary marker with an SN range from 89% to 96.4% and an SP range from 95% to 100% (Shirodkar and Lokeshwar 2009; Konety et al. 2000; Feng et al. 2011). A meta-analysis summarized the pooled SN of 0.93 (95% CI, 0.90–0.95) and the pooled SP of 0.97 (95% CI, 0.95–0.98), which represent a promising diagnostic marker in BC (Cai et al. 2015). Alavi et al. reported significantly higher BLCA-4 urine levels in patients with BC (p < 0.001), while tumor stage and size showed no association (Alavi et al. 2019).
ORM1 (Orosomucoid-1) plays an important role in modulating the activity of the immune system during acute-phase reactions and other chronic diseases (Hou et al. 2014). Urinary ORM1 levels were identified and significantly elevated in BC compared to healthy controls by proteomic methods, and an optimum cut-off value of 3912.97 ng/mg corresponding to 91.96% SN and 94.34% SP was identified. A cut-off value of 7351.28 ng/mg was utilized to distinguish infiltrating urothelial carcinoma from BC patients corresponding to 91.89% SN and 90.67% SP (Li et al. 2016).
HTRA1 (high-temperature requirement 1)—a member of the family of HtrA proteins, is a secreted multidomain protein with serine protease activity (Clausen et al. 2002). Changes in its expression associated with tumorigenesis have been reported, e.g., HtrA1 down-regulation has been described in human ovarian cancer (Shridhar et al. 2002). Also, its over-expression was detected to suppress the proliferation and migration of tumor cells in highly invasive melanoma (Baldi et al. 2002). In various solid tumors, such as ovarian and lung cancer the expression of HtrA1 is down-regulated (Chien et al. 2004; Esposito et al. 2006). In the study by Lorenzi et al. the SN/SP values calculated at a cut-off value of 1.48 (HtrA1), were 92.65% (C.I. 86.44–98.85%) and 95.59% (C.I. 90.7–99.7%), respectively. Highlighting a very good global performance of the diagnostic test (AUC is equal to 0.9839, C.I. 0.97–0.99) (PPV = 95.45% (C.I. 90.42–99.7%, NPV = 92.86%) (Lorenzi et al. 2013). Recently, a meta-analysis was conducted to assess the potential role of HtrA1 as a tumor marker and/or prognostic factor in several tumors (Altobelli et al. 2018). There was a statistically significant difference between the tumor samples and healthy controls, with a consistent finding of this work, that HtrA1 levels are higher in healthy controls or normal-looking tissue than in diseased tissue from patients with a variety of tumors. This implies that HtrA1 could be a promising biomarker in BC.
Keratin 17 (K17) is a type I cytokeratin found in various epidermal appendages such as hair follicles or sebaceous glands. The presence of K17 in the urine of patients with BC is the newest significant biomarker currently under study. The test kit is used under the name of Uro17™. Vasdev et al., reported SN/SP of 100%/92.6% for both NMIBC and MIBC detection (Vasdev et al. 2021). Babu et al. reported an SN of 89% with an SP of 88% for distinguishing between malignant and normal tissue in biopsies (Babu et al. 2019). Babu et al. also found that only five K17-positive cells were sufficient threshold for a positive test (AUC = 0.90), where SN ranged from 86% or 97%, the first for a biopsy-confirmed BC, the second in a discovery and validation cohort, while and SP of 100% for high-grade and 84% for biopsy-confirmed tumors (Babu et al. 2021). Elevated expression of K17 in BC cells on mRNA and protein levels was found in comparison with the normal human urothelial cells (Li et al. 2021).
Glycomic biomarkers
Glycomic biomarkers comprise:
-
Glycoproteins are presented in Table 2, of which only the first four are included for lack of information on the ones currently under investigation.
-
Markers of glycosylation.
Glycoproteins
Glycoprotein HOMER3 can be found in BC at the cell surface covered with short-chain sialylated O-glycans and was identified as a potential predictor of the worst prognosis of BC, and its expression was hypothesized to be driven by hypoxia and glucose deprivation. Analyzed were BC cell lines of grade I–IV and 104 FFPE BC tissue samples. The result of the HOMER3 knockdown was a decrease in proliferation and on the opposite, after the HOMER3 knock-in there was an increase in its membrane expression. HOMER3 expression was not noticed in healthy urothelial tissue. Using mass spectrometry (MS) were also identified potentially important domains in HOMER3-glycosides of BC tissues. HOMER3-STn glycoforms look promising in the case of precise targeting for clinics (Peixoto et al. 2021).
Fibronectin, laminin-5, and type IV collagen are glycoproteins present in the urothelial basement membrane (UBM), and all bladder cancer staging over Ta (T1–T4) may demonstrate disturbances in the UBM structure, as well as alterations in the serum concentrations of UBM proteins. These proteins were analyzed using surface plasmon resonance imaging (SPRi) biosensors in 92 serum samples with different BC characteristics. Differentiation between controls and BC samples showed satisfactory results with AUC scores of 0.92–0.99. The sensitivity of the assay was 98–100% and the specificity was 62–92%, which can be a good predictor in the early detection of BC (Guszcz et al. 2023).
The poor prognosis of urothelial carcinoma relates to higher expression of Glucosidase II α-subunit (GANAB protein), which is a regulator of glycosylation that could be used as a prognostic biomarker for urothelial carcinoma. 107 FFPE samples and two cell lines were analyzed using immunohistochemistry (IHC) assay, and upregulated expression of GANAB was in correlation with high tumor grades, promoting proliferation, invasion, or migration of carcinoma cells. This protein can serve as a prognostic biomarker correlated with unfavorable outcomes of urothelial carcinoma (Lin et al. 2022).
Beta-subunit of prolyl 4-hydroxylase (P4HB) glycoprotein having also impact on N-glycan modification in endoplasmic reticulum was studied as a novel biomarker with diagnostic and prognostic value in diagnostic of BC. 69 pairs of BC and control tissues were analyzed, and the AUC value for expression of P4HB to discriminate between tumor and normal control tissues was up to 0.881 (95% CI: 0.825–0.937; p < 0.001) (Wu et al. 2021).
In the study with 417 FFPE BC samples by IHC and bioinformatic tools, versican, a chondroitin sulfate proteoglycan, was identified as a prognostic marker upregulated in BC (Zhang et al. 2021). Other newly studied glycoproteins with a promising outlook for the characterization of grade, progression, or implementation of better-targeted therapy of BC are listed in Table 2, while their association with BC is presented in Fig. 1.
Markers of glycosylation
The importance of glycomic biomarkers, biomarkers based on the detection of altered glycosylation, for early diagnosis, prognosis, and therapy of many diseases, including cancer, is growing rapidly, and this applies to BC as well. In recent years, there were several published reviews dedicated to the glycan and glycoprotein changes related to BC (Jian et al. 2020; Jin et al. 2021; López-Cortés et al. 2021; Wilson et al. 2021). In this section, we discuss the newest research on BC glycomic biomarkers that were reported during the last 2 years.
Glycosylation changes on glycoprotein CD44 were studied with 75 FFPE patients’ bladder tumor tissues (34 NMIBC, 41 MIBC), 11 control tissues, and 3 cell lines of BC by a combination of various approaches, glycomics including several types of immunoassays and double staining immunofluorescence, glycoproteomics and transcriptomic, for better and more complex characterization of samples. CD44-Tn/Sialyl-Tn (STn) glycoforms were identified as the important signatures of aggressiveness in the case of BC requiring targeted interventions (Gaiteiro et al. 2022).
Characterization and differences in glycosylation between low-grade BC, high-grade BC, and control epithelial cells were studied using various glycomics approaches. Cell lines containing cells with low-grade BC (RT4, 5637, SW780) showed higher expression of fucosylated Lewis X (LeX) antigen in comparison with control bladder cells of epithelium (A/T/N), while in the high-grade BC cell lines (J82COT, T24, TCCSUP), there was only a little or no expression of LeX reported. Some other differences in fucosylation and sialylation of N-glycans were identified between these three groups as well. Moreover, different expression of glycosyltransferases between low-grade and high-grade BC cell lines were related to different expression of O-glycans (Ezeabikwa et al. 2021). Determination of cells' surface truncated O-glycans in relation to more types of cancers including BC revealed that Tn and STn expression is decreasing with higher tumor grade (Rømer et al. 2021).
Analysis of BC urine biomarker, UMOD glycoprotein that is present in the urine of people with BC, and lamprey immunity protein (LIP), a lectin that specifically binds to multi-antennary sialylated N-glycolylneuraminic acid (Neu5Gc) structures on UMOD glycoproteins in the urine of BCa patients, was performed in ELISA format. The number of samples for this primary screening was over 3500 samples of different stages (BC, benign, controls). The AUC (95%) value was 0.9422 when the benign group was chosen as the control. The results indicate that Neu5Gc-modified UMOD glycoproteins present in urine and sialyltransferases may function as potential markers in clinical trials, and LIP may be a tool for early BCa identification, diagnosis, and monitoring (Teng et al. 2022).
The discrimination between urothelial carcinoma (UC), including BC and upper urinary tract UC (UTUC) was performed by studying N-glycans on immunoglobulin using gel electrophoresis (GE) on 104 BC, 68 UTUC, 62 controls, 10 urinary tract infections, and 5 cystitis serum samples. BC and UTUC scores for discriminating BC and UTUC were defined by AUC, 0.977 and 0.867 (Kodama et al. 2021). In another study, the diagnostic of 9 urological diseases, including BC, was performed by characterization of N-glycan signatures of immunoglobulin (Ig). 1213 serum samples, 176 of them from BC patients and 269 healthy volunteers were analyzed by CE and data were processed by machine learning to obtain characteristic Ig N-glycan signatures for these nine diseases. A combination of α-2,3 sialyl tetraantennary N-glycan and agalactosyl bisecting GlcNAc core fucosyl N-glycan was sufficient for specific detection of BC. The AUC and specificity at 90% sensitivity of the BC score versus seven diseases had a high value (0.99% and 98%, respectively), and urinary tract infection had a lower value (0.90% and 77.0%, respectively) (Iwamura et al. 2022).
Upregulation of glycosyltransferase C1GALT1 was found in serum and tissue samples from BC patients. Moreover, this transferase is responsible for the production of T antigen, which was also upregulated in high-grade BC (Tan et al. 2022).
A recent study refuted the previous claims about down-regulation in the expression of ST6GAL1 in the case of BC. The ST6GAL1 Golgi sialyltransferase is upregulated in many human malignancies, however, many commercial antibodies for ST6GAL1 do not, in fact, recognize ST6GAL1, what was the reason for this mistake? The samples were analyzed using tissue microarrays with IHC staining, and this result is in correlation with those obtained for other cancers (Haldar et al. 2022).
Disruption of N-glycan expression in pancreatic adenocarcinoma to reverse the resistance of tumor cells to be killed by chimeric antigen receptor (CAR) T cells was studied by two different approaches, ablation of MGAT5 (mannoside acetyl-glucosaminyltransferase 5) in tumor cells or treating of mice with 2-deoxy-d-glucose. The approach of treating with 2-deoxy-d-glucose with CAR T cells was also efficient for other types of cancer, including BC. It was found a negative correlation between the expression of N-glycans and the killing potency of CAR T cells can be considered a predictive biomarker in patients with ineffective CAR T cell therapy (Greco et al. 2022).
Conclusion and future directions
There are a few new and notable markers, e.g., serum irisin, that in a new study, fell only a little short of the 90% threshold of SN/SP, with promising results to differentiate NMIBC from MIBC with a sensitivity of 75% and specificity of 73.7% (Taken et al. 2022). Future use of irisin in protein panels seems a viable option, however, this diagnostic method needs to be more researched to reach better results. Also, a recent meta-analysis connected Human papillomavirus (HPV) to a possibly higher susceptibility for BC and a worse prognosis (Sun et al. 2023). HPV is long connected to higher susceptibility and worse outcomes of cervical and penile cancers, it is only expected that the virus can travel through the urethra and affect the bladder (Okunade 2020; Iorga et al. 2020; Kidd et al. 2017). A study by Wang et al., on BC patients’ routine blood and urine parameters reported an association of higher urine pH with decreased risk of BC. Protein, glucose, and occult blood in urine showed an association with an increased risk of BC (Wang et al. 2021). Singh et al. reported elevated serum HMGB-1 levels in UBC patients with a positive correlation with disease severity and clinicopathological parameters (Singh et al. 2022). Aurora kinase and p53 family members expression studied in human BC cells showed, that in tumors with low p53 expression, the presence of either high AURKA or AURKB expression levels predicted an increased risk for relapse and mortality and high baseline AURKA expression predicted for inferior OS (Burgess et al. 2022). Bausch et al. investigated the association between urinary calprotectin and sterile leukocyturia in LG and HG BC, however, calprotectin did not qualify as a standalone marker, but rather a surrogate marker for tumor inflammation (Bausch et al. 2019).
Sangster et al. studied mutations in MIBC which is characterized by an abundance of mutations especially in chromatin modification and DNA damage response genes and reported two mutually exclusive mutation patterns in KDM6A and KMT2D as well as KDM6A and RB1, pointing to possible mutational interactions in BC (Sangster et al. 2022). A recent trial on the association of lncRNA and immunotherapy response including patients with BC showed that low and high scores of lncRNA differed significantly in overall survival, AUC on 12/20 months 0.79 and 0.77, respectively (Yu et al. 2020). Earlier this year, HLA-A*03 was associated with reduced overall survival after treatment with immune checkpoint inhibitors in the JAVELIN Solid Tumour trial (Naranbhai et al. 2022). The proposition for a novel BC biomarker is the 50 bp insertion/deletion polymorphism in superoxide dismutase (SOD1), where the SOD1 50-bp Ins/Del genotype, as well as Del, allele, was positively correlated with an elevated risk for BC in the Iranian population (Sarabandi et al. 2022).
In conclusion, the field of protein biomarkers is a vast one, studied for many decades either by histological staining or IHC methods. In recent years, gene expressions, epigenetic modifications, glycosylation, and analysis of extracellular vesicles (EVs) or non-coding RNA (ncRNA) have become the preferred and much-anticipated research standard. Various biomarkers have been identified using these methods, trying to make the diagnostic process more specific (Repiska et al. 2010). For BC, we chose the ones in the main text based on their significance and impact on BC diagnosis, recurrence, and progression. As seen in our review, the field of biomarkers is also a fast-growing one, fueled by rising cancer prevalence and the many issues of its diagnostics and therapy. Establishing tests and diagnostic methods to better and earlier determine cancer susceptibility, incidence, progression, or recurrence is an uneasy quest; however, a necessary one, for despite our best intentions, the incidence rises. Many patients ignore screening and advanced stages are harder or impossible to treat, while the number of specialists is also finite.
References
Adamia S, Maxwell CA, Pilarski LM (2005) Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 5:3–14. https://doi.org/10.2174/1568006053005056
Al Khader A, Fararjeh AFS, Kaddumi EG, Al-Saghbini M (2022) Significance of fibulin-3 expression in bladder cancer: a tissue microarray-based immunohistochemical study. World J Surg Oncol 20:133. https://doi.org/10.1186/s12957-022-02597-z
Alavi A, Izadpanahi M-H, Haghshenas L, Faridizad R, Eslami M-J, Ghadimi K (2019) Comparing urine levels of BLCA-4 nuclear matrix protein in patients with bladder cancer and non-bladder cancer. Int J Physiol Pathophysiol Pharmacol 11:289–292
Altobelli E, Angeletti PM, Morroni M, Profeta VF (2018) HtrA1 as a promising tissue marker in cancer: a meta-analysis. BMC Cancer 18:143. https://doi.org/10.1186/s12885-018-4041-2
Amano N, Matsumoto K, Shimizu Y, Nakamura M, Tsumura H, Ishii D et al (2021) High HNRNPA3 expression is associated with lymph node metastasis and poor prognosis in patients treated with radical cystectomy. Urol Oncol 39:196.e1-196.e7. https://doi.org/10.1016/j.urolonc.2020.10.072
Babu S, Mockler DC, Roa-Peña L, Szygalowicz A, Kim NW, Jahanfard S et al (2019) Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia. Mod Pathol 32:717–724. https://doi.org/10.1038/s41379-018-0177-5
Babu S, Kim NW, Wu M, Chan I, Escobar-Hoyos LF, Shroyer KR (2021) Keratin 17 is a novel cytologic biomarker for urothelial carcinoma diagnosis. Am J Clin Pathol 156:926–933. https://doi.org/10.1093/ajcp/aqab050
Baldi A, De Luca A, Morini M, Battista T, Felsani A, Baldi F et al (2002) The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells. Oncogene 21:6684–6688. https://doi.org/10.1038/sj.onc.1205911
Bansal N, Gupta AK, Gupta A, Sankhwar SN, Mahdi AA (2016) Serum-based protein biomarkers of bladder cancer: A pre- and post-operative evaluation. J Pharm Biomed Anal 124:22–25. https://doi.org/10.1016/j.jpba.2016.02.026
Bausch K, Roth E, Heinz S, Horst D, Mathia S, Vlajnic T et al (2019) Urinary calprotectin loses specificity as tumour marker due to sterile leukocyturia associated with bladder cancer. PLoS ONE 14:e0213549. https://doi.org/10.1371/journal.pone.0213549
Bevizova K, Jakubovsky J, Luha J, Novakova Z, Polak S (2013) Immunohistochemical analysis of urothelial bladder cancers. Online J Biol Sci 13:66–71. https://doi.org/10.3844/ojbssp.2013.66.71
Burgess EF, Livasy C, Trufan S, Zhu J, O’Connor HF, Hartman A et al (2022) Clinical outcomes associated with expression of aurora kinase and p53 family members in muscle-invasive bladder cancer. Mol Clin Oncol 16:102. https://doi.org/10.3892/mco.2022.2535
Cai Q, Wu Y, Guo Z, Gong R, Tang Y, Yang K et al (2015) Urine BLCA-4 exerts potential role in detecting patients with bladder cancers: a pooled analysis of individual studies. Oncotarget 6:37500–37510. https://doi.org/10.18632/oncotarget.6061
Candido S, Di Maso M, Serraino D, McCubrey JA, Bortolus R, Zanin M et al (2016) Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder. Tumour Biol 37:9855–9863. https://doi.org/10.1007/s13277-016-4872-x
Chang Y, Jin H, Li H, Ma J, Zheng Z, Sun B et al (2020) MiRNA-516a promotes bladder cancer metastasis by inhibiting MMP9 protein degradation via the AKT/FOXO3A/SMURF1 axis. Clin Transl Med 10:e263. https://doi.org/10.1002/ctm2.263
Chien J, Staub J, Hu S-I, Erickson-Johnson MR, Couch FJ, Smith DI et al (2004) A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer. Oncogene 23:1636–1644. https://doi.org/10.1038/sj.onc.1207271
Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS et al (2009) Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol 182:2625–2631. https://doi.org/10.1016/j.juro.2009.08.083
Clausen T, Southan C, Ehrmann M (2002) The HtrA family of proteases: implications for protein composition and cell fate. Mol Cell 10:443–455. https://doi.org/10.1016/s1097-2765(02)00658-5
Dong Y, Zhang T, Li X, Yu F, Yu H, Shao S (2021) Urine biomarkers for the diagnosis of bladder cancer: a network meta-analysis. Urol J 18:623–632. https://doi.org/10.22037/uj.v18i.6254
Dong Y, Ding D, Gu J, Chen M, Li S (2022) Alpha-2 Heremans Schmid glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-β signalling pathway. Bioengineered 13:14282–14298. https://doi.org/10.1080/21655979.2022.2081465
EAU Guidelines (2020) Edn. presented at the EAU Annual Congress Amsterdam 2020. n.d.
EAU Guidelines (2021) Edn. Presented at the EAU Annual Congress Milan 2021. n.d.
EAU Guidelines (2022) Edn. Presented at the EAU Annual Congress Amsterdam 2022. n.d.
EAU Guidelines (2023) Edn. Presented at the EAU Annual Congress Milan 2023. n.d.
Eissa S, Kassim SK, Labib RA, El-Khouly IM, Ghaffer TM, Sadek M et al (2005) Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer 103:1356–1362. https://doi.org/10.1002/cncr.20902
Esposito V, Campioni M, De Luca A, Spugnini EP, Baldi F, Cassandro R et al (2006) Analysis of HtrA1 serine protease expression in human lung cancer. Anticancer Res 26:3455–3459
Ezeabikwa B, Mondal N, Antonopoulos A, Haslam SM, Matsumoto Y, Martin-Caraballo M et al (2021) Major differences in glycosylation and fucosyltransferase expression in low-grade versus high-grade bladder cancer cell lines. Glycobiology 31:1444–1463. https://doi.org/10.1093/glycob/cwab083
Feng CC, Wang PH, Guan M, Jiang HW, Wen H, Ding Q et al (2011) Urinary BLCA-4 is highly specific for detection of bladder cancer in Chinese Han population and is related to tumour invasiveness. Folia Biol (Praha) 57:242–247
Fukumoto K, Kikuchi E, Mikami S, Miyajima A, Oya M (2016) Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin. BMC Urol 16:5. https://doi.org/10.1186/s12894-016-0122-1
Gaiteiro C, Soares J, Relvas-Santos M, Peixoto A, Ferreira D, Paulo P et al (2022) Glycoproteogenomics characterizes the CD44 splicing code associated with bladder cancer invasion. Theranostics 12:3150–3177. https://doi.org/10.7150/thno.67409
Golshani R, Hautmann SH, Estrella V, Cohen BL, Kyle CC, Manoharan M et al (2007) HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer 120:1712–1720. https://doi.org/10.1002/ijc.22222
Golshani R, Lopez L, Estrella V, Kramer M, Iida N, Lokeshwar VB (2008) Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68:483–491. https://doi.org/10.1158/0008-5472.CAN-07-2140
Grebhardt S, Müller-Decker K, Bestvater F, Hershfinkel M, Mayer D (2014) Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo. J Cell Physiol 229:661–671. https://doi.org/10.1002/jcp.24489
Greco B, Malacarne V, De Girardi F, Scotti GM, Manfredi F, Angelino E et al (2022) Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci Transl Med 14:eabg3072. https://doi.org/10.1126/scitranslmed.abg3072
Guan Z, Sun Y, Mu L, Jiang Y, Fan J (2022) Tenascin-C promotes bladder cancer progression and its action depends on syndecan-4 and involves NF-κB signaling activation. BMC Cancer 22:240. https://doi.org/10.1186/s12885-022-09285-x
Gupta A, Bansal N, Mitash N, Kumar D, Kumar M, Sankhwar SN et al (2020) NMR-derived targeted serum metabolic biomarkers appraisal of bladder cancer: a pre- and post-operative evaluation. J Pharm Biomed Anal 183:113134. https://doi.org/10.1016/j.jpba.2020.113134
Guszcz T, Sankiewicz A, Gorodkiewicz E (2023) Application of surface plasmon resonance imaging biosensors for determination of fibronectin, laminin-5 and type IV collagen in serum of transitional bladder cancer patients. J Pharm Biomed Anal 222:115103. https://doi.org/10.1016/j.jpba.2022.115103
Haldar B, Hwang J, Narimatsu Y, Clausen H, Bellis SL (2022) The incorrect use of CD75 as a synonym for ST6GAL1 has fostered the expansion of commercial “ST6GAL1” antibodies that do not recognize ST6GAL1. Glycobiology 32:736–742. https://doi.org/10.1093/glycob/cwac043
Han C, Chen S, Ma H, Wen X, Wang Z, Xu Y et al (2021) RPN2 predicts poor prognosis and promotes bladder cancer growth and metastasis via the PI3K-Akt pathway. Onco Targets Ther 14:1643–1657. https://doi.org/10.2147/OTT.S300480
Harada J, Miyata Y, Araki K, Matsuda T, Nagashima Y, Mukae Y et al (2021) Pathological significance and prognostic roles of thrombospondin-3, 4 and 5 in bladder cancer. In Vivo 35:1693–1701. https://doi.org/10.21873/invivo.12429
Hou L, Li F, Zeng Q, Su L, Chen P, Xu Z et al (2014) Excretion of urinary orosomucoid 1 protein is elevated in patients with chronic heart failure. PLoS ONE 9:e107550. https://doi.org/10.1371/journal.pone.0107550
Huang Y-L, Chen J, Yan W, Zang D, Qin Q, Deng A-M (2015) Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21–1) for bladder cancer: a systematic review and meta-analysis. Tumour Biol 36:3137–3145. https://doi.org/10.1007/s13277-015-3352-z
Iorga L, Dragos Marcu R, Cristina Diaconu C, Maria Alexandra Stanescu A, Pantea Stoian A, Liviu Dorel Mischianu D et al (2020) Penile carcinoma and HPV infection (review). Exp Ther Med 20:91–96. https://doi.org/10.3892/etm.2019.8181
Itano N, Sawai T, Atsumi F, Miyaishi O, Taniguchi S, Kannagi R et al (2004) Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem 279:18679–18687. https://doi.org/10.1074/jbc.M313178200
Iwamura H, Mizuno K, Akamatsu S, Hatakeyama S, Tobisawa Y, Narita S et al (2022) Machine learning diagnosis by immunoglobulin N-glycan signatures for precision diagnosis of urological diseases. Cancer Sci 113:2434–2445. https://doi.org/10.1111/cas.15395
Jazayeri MH, Aghaie T, Nedaeinia R, Manian M, Nickho H (2020) Rapid noninvasive detection of bladder cancer using survivin antibody-conjugated gold nanoparticles (GNPs) based on localized surface plasmon resonance (LSPR). Cancer Immunol Immunother 69:1833–1840. https://doi.org/10.1007/s00262-020-02559-y
Jeong H, Oh HE, Kim H, Lee J-H, Lee ES, Kim Y-S et al (2021) Upregulation of fatty acid transporters is associated with tumor progression in non-muscle-invasive bladder cancer. Pathol Oncol Res 27:594705. https://doi.org/10.3389/pore.2021.594705
Jian Y, Xu Z, Xu C, Zhang L, Sun X, Yang D et al (2020) The roles of glycans in bladder cancer. Front Oncol 10:957. https://doi.org/10.3389/fonc.2020.00957
Jin F, Shahid M, Kim J (2021) Research progress of urine biomarkers in the diagnosis, treatment, and prognosis of bladder cancer. Adv Exp Med Biol 1306:61–80. https://doi.org/10.1007/978-3-030-63908-2_5
Kaseb H, Aeddula NR (2023) Bladder cancer. StatPearls Publishing, StatPearls, Treasure Island, FL
Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P (2017) Relationship between human papillomavirus and penile cancer—implications for prevention and treatment. Transl Androl Urol 6:791–802. https://doi.org/10.21037/tau.2017.06.27
Kimura S, Soria F, D’Andrea D, Foerster B, Abufaraj M, Vartolomei MD et al (2018) Prognostic value of serum cholinesterase in non-muscle-invasive bladder cancer. Clin Genitourin Cancer 16:e1123–e1132. https://doi.org/10.1016/j.clgc.2018.07.002
Kodama H, Yoneyama T, Tanaka T, Noro D, Tobisawa Y, Yamamoto H et al (2021) N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas. Cancer Med 10:1297–1313. https://doi.org/10.1002/cam4.3727
Konety BR, Nguyen TS, Dhir R, Day RS, Becich MJ, Stadler WM et al (2000) Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. Clin Cancer Res 6:2618–2625
Kramer MW, Golshani R, Merseburger AS, Knapp J, Garcia A, Hennenlotter J et al (2010) HYAL-1 hyaluronidase: a potential prognostic indicator for progression to muscle invasion and recurrence in bladder cancer. Eur Urol 57:86–93. https://doi.org/10.1016/j.eururo.2009.03.057
Kramer MW, Escudero DO, Lokeshwar SD, Golshani R, Ekwenna OO, Acosta K et al (2011) Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 117:1197–1209. https://doi.org/10.1002/cncr.25565
Kuo Y-H, Lai H-Y, Chan T-C, Hsing C-H, Huang SK, Hsieh K-L et al (2022) Upregulation of cartilage oligomeric matrix protein predicts poor prognosis in urothelial carcinoma. Onco Targets Ther 15:727–740. https://doi.org/10.2147/OTT.S370028
Lee D, Lee W, Kim H-P, Kim M, Ahn HK, Bang D et al (2023) Accurate detection of urothelial bladder cancer using targeted deep sequencing of urine DNA. Cancers 15:2868. https://doi.org/10.3390/cancers15102868
Li F, Yu Z, Chen P, Lin G, Li T, Hou L et al (2016) The increased excretion of urinary orosomucoid 1 as a useful biomarker for bladder cancer. Am J Cancer Res 6:331–340
Li J-R, Chiu K-Y, Ou Y-C, Wang S-S, Chen C-S, Yang C-K et al (2019) Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma. BioFactors 45:62–68. https://doi.org/10.1002/biof.1460
Li C, Su H, Ruan C, Li X (2021) Keratin 17 knockdown suppressed malignancy and cisplatin tolerance of bladder cancer cells, as well as the activation of AKT and ERK pathway. Folia Histochem Cytobiol 59:40–48. https://doi.org/10.5603/FHC.a2021.0005
Lin Q, Pei L, Zhao Z, Zhuang X, Qin H (2022) Glycoprotein α-subunit of glucosidase II (GIIα) is a novel prognostic biomarker correlated with unfavorable outcome of urothelial carcinoma. BMC Cancer 22:817. https://doi.org/10.1186/s12885-022-09884-8
Liu F, Zhang H, Xie F, Tao D, Xiao X, Huang C et al (2020) Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491-5p/MMP9 axis. Oncogene 39:1696–1709. https://doi.org/10.1038/s41388-019-1092-z
López-Cortés R, Gómez BB, Vázquez-Estévez S, Pérez-Fentes D, Núñez C (2021) Blood-based protein biomarkers in bladder urothelial tumors. J Proteomics 247:104329. https://doi.org/10.1016/j.jprot.2021.104329
Lorenzi T, Lorenzi M, Altobelli E, Marzioni D, Mensà E, Quaranta A et al (2013) HtrA1 in human urothelial bladder cancer: a secreted protein and a potential novel biomarker. Int J Cancer 133:2650–2661. https://doi.org/10.1002/ijc.28280
Lotan Y, Roehrborn CG (2003) Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61:109–118. https://doi.org/10.1016/s0090-4295(02)02136-2. (discussion 118)
Mammadov E, Aslan G, Tuna B, Bozkurt O, Yorukoglu K (2014) Can recurrence and progression be predicted by HYAL-1 expression in primary T1 bladder cancer? Asian Pac J Cancer Prev 15:10401–10405. https://doi.org/10.7314/apjcp.2014.15.23.10401
Medscape. Urine test predicts future bladder cancer 12 years before symptoms. Medscape n.d. https://www.medscape.com/viewarticle/989553. Accessed 23 May 2023
Mori K, Schuettfort VM, Katayama S, Laukhtina E, Pradere B, Quhal F et al (2022) Prognostic role of preoperative vascular cell adhesion molecule-1 plasma levels in urothelial carcinoma of the bladder treated with radical cystectomy. Ann Surg Oncol 29:5307–5316. https://doi.org/10.1245/s10434-022-11575-4
Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C et al (2022) HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol 23:172–184. https://doi.org/10.1016/S1470-2045(21)00582-9
Novakova ZV, Bevizova K, Gasparova I (2014) Novel biomarkers in determining prostate cancer diagnosis and prognosis. Online J Biol Sci 14:277–285. https://doi.org/10.3844/ojbsci.2014.277.285
Okunade KS (2020) Human papillomavirus and cervical cancer. J Obstet Gynaecol 40:602–608. https://doi.org/10.1080/01443615.2019.1634030
Orywal K, Jelski W, Werel T, Szmitkowski M (2017) The diagnostic significance of serum alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase activity in urinary bladder cancer patients. Anticancer Res 37:3537–3541. https://doi.org/10.21873/anticanres.11722
Orywal K, Jelski W, Werel T, Szmitkowski M (2018) The activity of class I–IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in bladder cancer cells. Cancer Invest 36:66–72. https://doi.org/10.1080/07357907.2017.1422511
Peixoto A, Ferreira D, Azevedo R, Freitas R, Fernandes E, Relvas-Santos M et al (2021) Glycoproteomics identifies HOMER3 as a potentially targetable biomarker triggered by hypoxia and glucose deprivation in bladder cancer. J Exp Clin Cancer Res 40:191. https://doi.org/10.1186/s13046-021-01988-6
Piao X-M, Kang HW, Jeong P, Byun YJ, Lee HY, Kim K et al (2021) A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urol Oncol 39:237.e21-237.e29. https://doi.org/10.1016/j.urolonc.2020.11.017
Qing L, Li Q, Yang Y, Xu W, Dong Z (2022) A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research. BMC Urol 22:114. https://doi.org/10.1186/s12894-022-01067-8
Repiska V, Radzo E, Biro C, Bevizova K, Bohmer D, Galbavy S (2010) Endometrial cancer—prospective potential to make diagnostic process more specific. Neuroendocrinol Lett 31:474–476
Rømer TB, Aasted MKM, Dabelsteen S, Groen A, Schnabel J, Tan E et al (2021) Mapping of truncated O-glycans in cancers of epithelial and non-epithelial origin. Br J Cancer 125:1239–1250. https://doi.org/10.1038/s41416-021-01530-7
Sangster AG, Gooding RJ, Garven A, Ghaedi H, Berman DM, Davey SK (2022) Mutually exclusive mutation profiles define functionally related genes in muscle invasive bladder cancer. PLoS ONE 17:e0259992. https://doi.org/10.1371/journal.pone.0259992
Sarabandi S, Effatpanah H, Sereshki N, Samavarchi Tehrani S, Moradi-Sardareh H (2022) 50-bp insertion/deletion polymorphism of the superoxide dismutase-1 is associated with bladder cancer risk in an Iranian population. Nucleosides Nucleotides Nucleic Acids 41:154–165. https://doi.org/10.1080/15257770.2021.2014521
Shirodkar SP, Lokeshwar VB (2009) Potential new urinary markers in the early detection of bladder cancer. Curr Opin Urol 19:488–493. https://doi.org/10.1097/MOU.0b013e32832eb3a0
Shridhar V, Sen A, Chien J, Staub J, Avula R, Kovats S et al (2002) Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res 62:262–270
Singh A, Gupta N, Khandakar H, Kaushal S, Seth A, Pandey RM et al (2022) Autophagy-associated HMGB-1 as a novel potential circulating non-invasive diagnostic marker for detection of urothelial carcinoma of bladder. Mol Cell Biochem 477:493–505. https://doi.org/10.1007/s11010-021-04299-8
Sun X, Xin S, Jin L, Zhang Y, Ye L (2022) Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer. Bioengineered 13:13986–13999. https://doi.org/10.1080/21655979.2022.2085284
Sun J-X, Xu J-Z, Liu C-Q, An Y, Xu M-Y, Zhong X-Y et al (2023) The association between human papillomavirus and bladder cancer: evidence from meta-analysis and two-sample mendelian randomization. J Med Virol 95:e28208. https://doi.org/10.1002/jmv.28208
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
Taken K, Aslan R, Eryilmaz R, Alp HH, Huyut Z, Dönmez Mİ (2022) Serum irisin is a novel biomarker for bladder cancer detection. Int Urol Nephrol 54:55–61. https://doi.org/10.1007/s11255-021-03074-4
Tan Z, Jiang Y, Liang L, Wu J, Cao L, Zhou X et al (2022) Dysregulation and prometastatic function of glycosyltransferase C1GALT1 modulated by cHP1BP3/ miR-1-3p axis in bladder cancer. J Exp Clin Cancer Res 41:228. https://doi.org/10.1186/s13046-022-02438-7
Teng H, Li Q, Gou M, Liu G, Cao X, Lu J et al (2022) Lamprey immunity protein enables early detection and recurrence monitoring for bladder cancer through recognizing Neu5Gc-modified uromodulin glycoprotein in urine. Biochim Biophys Acta Mol Basis Dis 1868:166493. https://doi.org/10.1016/j.bbadis.2022.166493
Vasdev N, Hampson A, Agarwal S, Swamy R, Chilvers M, Hampson A et al (2021) The role of URO17™ biomarker to enhance diagnosis of urothelial cancer in new hematuria patients—first European data. BJUI Compass 2:46–52. https://doi.org/10.1002/bco2.50
Wang D-Q, Shuai J, Zheng H, Guo Z-Q, Huang Q, Xu X-F et al (2021) Can routine blood and urine parameters reveal clues to detect bladder cancer? A case–control study. Front Oncol 11:796975. https://doi.org/10.3389/fonc.2021.796975
Wilson JL, Antoniassi MP, Lopes PI, Azevedo H (2021) Proteomic research and diagnosis in bladder cancer: state of the art review. Int Braz J Urol 47:503–514. https://doi.org/10.1590/S1677-5538.IBJU.2021.99.02
Wu Y, Peng Y, Guan B, He A, Yang K, He S et al (2021) P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma. Oncol Lett 21:95. https://doi.org/10.3892/ol.2020.12356
Yasar O, Akcay T, Obek C, Turegun FA (2017) Significance of S100A8, S100A9 and calprotectin levels in bladder cancer. Scand J Clin Lab Invest 77:437–441. https://doi.org/10.1080/00365513.2017.1336567
Yu Y, Zhang W, Li A, Chen Y, Ou Q, He Z et al (2020) Association of long noncoding RNA biomarkers with clinical immune subtype and prediction of immunotherapy response in patients with cancer. JAMA Netw Open 3:e202149. https://doi.org/10.1001/jamanetworkopen.2020.2149
Zhang Q, Wu J, Chen X, Zhao M, Zhang D, Gao F (2021) Upregulation of Versican associated with tumor progression, metastasis, and poor prognosis in bladder carcinoma. Biomed Res Int 2021:6949864. https://doi.org/10.1155/2021/6949864
Zheng X, Xu H, Lin T, Tan P, Xiong Q, Yi X et al (2022) CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer. Comput Biol Med 147:105727. https://doi.org/10.1016/j.compbiomed.2022.105727
Funding
Open access funding provided by The Ministry of Education, Science, Research and Sport of the Slovak Republic in cooperation with Centre for Scientific and Technical Information of the Slovak Republic. This publication was supported by the Operational Programme Integrated Infrastructure for the project: Increasing the Capacities and Competencies of the Comenius University in Research, Development, and Innovation 313021BUZ3, co-financed from the resources of the European Regional Development Fund.
Author information
Authors and Affiliations
Contributions
All authors participated in the conceptualization and design of the article; SH, KK, and SZ contributed to methodology, investigation, data curation, formal analysis, and writing of the original draft; JK and LD performed validation and review of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflicts of interest concerning the research, authorship, and/or publication of this article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Harsanyi, S., Kianickova, K., Katrlik, J. et al. Current look at the most promising proteomic and glycomic biomarkers of bladder cancer. J Cancer Res Clin Oncol 150, 96 (2024). https://doi.org/10.1007/s00432-024-05623-7
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00432-024-05623-7